Insys Therapeutics Hires Four Key Pharmaceutical Industry Veterans for Leadership Positions
June 20 2017 - 6:50AM
Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”)
today announced the addition of four pharmaceutical industry
veterans to its management team. Joining Insys are:
- Brian Jennings, Vice President of Sales
- Dr. Dean Mariano, Senior Director, Clinical Development/Medical
Affairs;
- Ariyapadi (Krishna) Krishnaraj, Vice President of Marketing and
Managed Care; and,
- Scott Warlick, General Manager, Manufacturing
“These key hires both elevate and diversify the talent within
this growing organization,” said Saeed Motahari, President and
Chief Executive Officer of Insys. “We are delighted to
welcome Brian, Dean, Krishna and Scott to the Company. Each of
these executives brings highly relevant experience to Insys, and we
look forward to their contributions as we execute our mission of
improving the quality of care for patients in need.”
Brian Jennings, Vice President of Sales, is a skilled executive
with more than 25 years of experience in the pharmaceutical
industry and has a proven track record of successfully developing,
motivating and leading commercial teams. Throughout his
extensive career, Mr. Jennings has held increasingly senior roles
at organizations including Publicis Healthcare Group, Sanofi, Roche
U.S. (Genentech), Unimed, and Searle. As Vice President of
Sales at Sanofi, he built and successfully managed Sanofi’s first
oncology sales force. While at Genentech, Mr. Jennings served
as the Director of Sales and drove growth for the oncology
portfolio. Prior to joining Insys, he served as the Regional
Business Director of Sales at Purdue Pharma.
Dr. Dean Mariano, Insys’ new Senior Director,
Clinical Development/Medical Affairs, is a practicing physician
focused on pain management treatments with clinical interest in
addiction and cancer patient populations. He has lectured
extensively across the country on the topic of safe opioid
prescribing. He was previously Medical Director at The Spine and
Pain Institute and Section Chief of Pain Medicine at MidState
Medical Center in Connecticut. Dr. Mariano is a Diplomat of the
American Board of Anesthesiology and holds a subspecialty
certification in Pain Medicine. His leadership positions
include President of the Connecticut Pain Society, Chairman of the
Connecticut State Medical Society’s Task Force on Opioids and
serves as a Ct. State Police Surgeon. He is a member of the
American Society of Anesthesiologists and is an Assistant Professor
at Quinnipiac University, Frank H. Netter, M.D. School of
Medicine.
Ariyapadi Krishnaraj joins Insys as Vice President of Marketing
and Managed Care with over 30 years of pharmaceutical industry
experience. As the Vice President of Marketing at Novartis, Mr.
Krishnaraj led the marketing and market research efforts to launch
innovative programs with pharmacies and develop global pricing
policies for vaccines. As an Executive Director at
GlaxoSmithKline, he successfully launched multiple products and
various patient-focused educational campaigns. Throughout his
career, he has successfully planned and built an
analytically-driven, patient-focused marketing and managed markets
teams. He most recently served at Iroko and as a consultant
for various pharmaceutical companies including Endo and Takeda.
Scott Warlick is a proven senior leader in the
pharmaceutical and specialty chemicals industry with over 25 years
of experience in pharmaceutical manufacturing plant experience
across operations, maintenance, process optimization, quality, and
safety. He was most recently Senior Director of Manufacturing
at Mylan Laboratories, prior to which Mr. Warlick was with
Mallinckrodt Pharmaceuticals where he held increasingly senior
positions across the manufacturing organization.
About Insys Therapeutics
Insys Therapeutics is a specialty pharmaceutical company that
develops and commercializes innovative drugs and novel drug
delivery systems of therapeutic molecules that improve the quality
of life of patients. Using proprietary sublingual spray technology
and capabilities to develop pharmaceutical cannabinoids, Insys is
developing a pipeline of products intending to address unmet
medical needs and the clinical shortcomings of existing commercial
products. Insys currently markets one product, SUBSYS® (fentanyl
sublingual spray), CII, and has received approval for the marketing
of SYNDROS™ (dronabinol) oral solution, CII, a proprietary, orally
administered liquid formulation of dronabinol that Insys believes
has distinct advantages over the current formulation of dronabinol
in soft gel capsule. Insys is committed to developing medications
for potentially treating addiction to opioids, opioid overdose,
epilepsy, and other disease areas with a significant unmet
need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development
Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements including
regarding our belief that SYNDROS™ has distinct advantages over the
current formulation of dronabinol in soft gel capsules.
These forward-looking statements are based on management's
expectations and assumptions as of the date of this press release;
actual results may differ materially from those in these
forward-looking statements as a result of various factors, many of
which are beyond our control. These factors include, but are not
limited to risk factors described in our filings with the United
States Securities and Exchange Commission, including those factors
discussed under the caption "Risk Factors" in our Annual Report on
Form 10-K for the year ended December 31, 2016 and subsequent
updates that may occur in our Quarterly Reports on Form 10-Q.
Forward-looking statements speak only as of the date of this press
release and we undertake no obligation to publicly update or revise
these statements, except as may be required by law.
NOTE: All trademarks and registered trademarks are the property
of their respective owners.
Investor Contact:
Lisa M. Wilson
President
In-Site Communication, Inc.
212-452-2793
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Mar 2024 to Apr 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Apr 2023 to Apr 2024